Dr John Maher leads the "CAR Mechanics" group within King's College London, which is focused on the development of adoptive immunotherapy using CAR and gamma delta T-cells. He played a key role in the early development of second generation CAR technology and is chief investigator of a Phase 1 CAR T-cell clinical trial in head and neck cancer. He is also a consultant immunologist within King's Health Partners and Eastbourne Hospital.
Abstract
The CAR mechanics group has a focus on the development of next generation CAR T-cell technologies that may find application in solid tumours, which heretofore have proven resistant to treatment using this approach. This presentation will span the bench to bedsite development of CAR T-cell immunotherapy, focussing on two target families that are widely expressed in pancreatic and other solid tumour types.